CN110088300A - 与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物 - Google Patents

与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物 Download PDF

Info

Publication number
CN110088300A
CN110088300A CN201780077861.1A CN201780077861A CN110088300A CN 110088300 A CN110088300 A CN 110088300A CN 201780077861 A CN201780077861 A CN 201780077861A CN 110088300 A CN110088300 A CN 110088300A
Authority
CN
China
Prior art keywords
allele
hla
tcdb
snp
drb1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077861.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·肖
D·V·梅赫罗特拉
R·L·布兰查德
沈具东
R·莫格
M·B·多尔
李俊桦
徐讯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGI Shenzhen Co Ltd
Merck Sharp and Dohme LLC
Original Assignee
BGI Shenzhen Co Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2016/109900 external-priority patent/WO2018107388A1/en
Application filed by BGI Shenzhen Co Ltd, Merck Sharp and Dohme LLC filed Critical BGI Shenzhen Co Ltd
Publication of CN110088300A publication Critical patent/CN110088300A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201780077861.1A 2016-12-14 2017-12-07 与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物 Pending CN110088300A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/109900 2016-12-14
PCT/CN2016/109900 WO2018107388A1 (en) 2016-12-14 2016-12-14 Human genetic markers associated with response to treatments that target clostridium difficile toxin b
US201762508066P 2017-05-18 2017-05-18
US62/508,066 2017-05-18
PCT/US2017/064985 WO2018111662A1 (en) 2016-12-14 2017-12-07 Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Publications (1)

Publication Number Publication Date
CN110088300A true CN110088300A (zh) 2019-08-02

Family

ID=62559092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780077861.1A Pending CN110088300A (zh) 2016-12-14 2017-12-07 与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物

Country Status (9)

Country Link
US (1) US12071666B2 (https=)
EP (1) EP3555303B1 (https=)
JP (3) JP2020502179A (https=)
CN (1) CN110088300A (https=)
AU (1) AU2017375590A1 (https=)
BR (1) BR112019012203A2 (https=)
MX (1) MX2019007012A (https=)
RU (1) RU2761249C2 (https=)
WO (1) WO2018111662A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112481395A (zh) * 2019-09-12 2021-03-12 深圳华大生命科学研究院 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071666B2 (en) * 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035265A1 (en) * 2008-07-18 2010-02-11 Aris Floratos Biomarkers for Drug-Induced Liver Injury
WO2010050829A1 (en) * 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
US20120156200A1 (en) * 2009-08-21 2012-06-21 Smithkline Beecham (Cork) Ltd. Method of treating cancer
CN103665141A (zh) * 2013-12-31 2014-03-26 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
CN104023748A (zh) * 2011-10-28 2014-09-03 诚信生物公司 含有氨基酸的蛋白质制剂
CN104039816A (zh) * 2012-01-27 2014-09-10 默沙东公司 包含重组毒素的针对艰难梭菌的疫苗
US20160145696A1 (en) * 2013-05-29 2016-05-26 Immunexpress Pty Ltd Microbial markers and uses therefor
US20200017909A1 (en) * 2016-12-14 2020-01-16 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2044591C (en) 1989-02-13 2002-08-13 James Langham Dale Detection of a nucleic acid sequence or a change therein
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
AU710425B2 (en) 1995-12-18 1999-09-23 Washington University Method for nucleic acid analysis using fluorescence resonance energy transfer
ES2215241T3 (es) 1996-11-06 2004-10-01 Sequenom, Inc. Procedimiento de espectrometria de masa.
DE19782097T1 (de) 1996-11-06 1999-10-14 Sequenom Inc Zusammensetzungen und Verfahren zur Immobilisierung von Nucleinsäuren an feste Träger
JP2010522560A (ja) * 2007-03-27 2010-07-08 デューク ユニバーシティ Ｈｉｖ疾患制限に関連する遺伝的変異体
PE20120056A1 (es) 2009-02-24 2012-02-05 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor crth2
SG10201701055WA (en) * 2011-09-16 2017-03-30 Ucb Pharma Sa Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
US10280470B2 (en) * 2013-01-11 2019-05-07 Baylor College Of Medicine Biomarkers of recurrent Clostridium difficile infection
US9181632B1 (en) * 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
WO2018107388A1 (en) 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100035265A1 (en) * 2008-07-18 2010-02-11 Aris Floratos Biomarkers for Drug-Induced Liver Injury
WO2010050829A1 (en) * 2008-10-31 2010-05-06 Vialactia Biosciences (Nz) Limited Marker assisted selection of a mammalian subject for desired immunoglobulin phenotype
US20120156200A1 (en) * 2009-08-21 2012-06-21 Smithkline Beecham (Cork) Ltd. Method of treating cancer
CN104023748A (zh) * 2011-10-28 2014-09-03 诚信生物公司 含有氨基酸的蛋白质制剂
CN104039816A (zh) * 2012-01-27 2014-09-10 默沙东公司 包含重组毒素的针对艰难梭菌的疫苗
US20160145696A1 (en) * 2013-05-29 2016-05-26 Immunexpress Pty Ltd Microbial markers and uses therefor
CN103665141A (zh) * 2013-12-31 2014-03-26 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
US20200017909A1 (en) * 2016-12-14 2020-01-16 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JUDONG SHEN等: "Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment", 《MSPHERE》 *
JUDONG SHEN等: "Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment", 《MSPHERE》, 6 May 2020 (2020-05-06), pages 00232 - 20 *
MARK WILCOX等: "Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II)", OPEN FORUM INFECTIOUS DISEASES, 9 December 2015 (2015-12-09) *
NCBI: "ss114142737(rs2516513)", 《DBSNP DATABASE》 *
NCBI: "ss114142737(rs2516513)", 《DBSNP DATABASE》, 29 March 2010 (2010-03-29), pages 2516513 *
ORTH, P.等: "Chain I, Bezlotoxumab Heavy Chain", GENBANK DATABASE, 16 July 2014 (2014-07-16), pages 4 *
ORTH, P.等: "Chain M, bezlotoxumab light chain", GENBANK DATABASE, 16 July 2014 (2014-07-16), pages 4 *
曹波: "我国部分地区艰难梭菌A/B毒素基因多态性研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 *
曹波: "我国部分地区艰难梭菌A/B毒素基因多态性研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, 15 August 2016 (2016-08-15), pages 060 - 141 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112481395A (zh) * 2019-09-12 2021-03-12 深圳华大生命科学研究院 艰难梭菌耐药/低敏感进化分支snp标记及菌株类别鉴定方法和应用

Also Published As

Publication number Publication date
EP3555303A4 (en) 2020-06-24
AU2017375590A1 (en) 2019-06-13
MX2019007012A (es) 2019-11-28
RU2019122099A3 (https=) 2021-04-16
JP2025061120A (ja) 2025-04-10
RU2019122099A (ru) 2021-01-15
JP2023055222A (ja) 2023-04-17
US20200017909A1 (en) 2020-01-16
WO2018111662A1 (en) 2018-06-21
EP3555303B1 (en) 2022-12-21
US12071666B2 (en) 2024-08-27
BR112019012203A2 (pt) 2019-11-12
RU2761249C2 (ru) 2021-12-06
EP3555303A1 (en) 2019-10-23
JP2020502179A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
US10878939B2 (en) Methods and compositions for personalized pain management
EP3129497B1 (en) Methods of selectively treating asthma using il-13 antagonists
US10465246B2 (en) Therapeutic regimen for hypertension
JP2025061120A (ja) クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー
CA3163367A1 (en) Biomarkers and uses thereof in the treatment of chronic hepatitis b infection
US20210348235A1 (en) Genetic markers associated with response to crth2 receptor antagonists
WO2018107388A1 (en) Human genetic markers associated with response to treatments that target clostridium difficile toxin b
CA2403937A1 (en) Iterative analysis of non-responding population in the design of pharmacogenetic studies
US20140011863A1 (en) Methods and compositions for assessment of pulmonary function and disorders
US20130281319A1 (en) Methods and compositions for assessment of pulmonary function and disorders
TW201343176A (zh) 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
EP1853909A2 (en) Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs
US20220259656A1 (en) Blood biomarker and genetic markers associated with response to crth2 receptor antagonists
WO2022049504A2 (en) Biomarkers and uses thereof in the treatment of chronic hbv infection
WO2002092838A2 (en) Allelic variants of delta opioid receptors associated with disorders of feeding and energy homeostasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination